Cargando…
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631640/ https://www.ncbi.nlm.nih.gov/pubmed/35834733 http://dx.doi.org/10.1182/bloodadvances.2022007708 |
_version_ | 1784823857471815680 |
---|---|
author | Hyak, Jonathan M. Huang, Ying Rogers, Kerry A. Bhat, Seema A. Grever, Michael R. Byrd, John C. Kittai, Adam S. Jones, Dan Miller, Cecelia R. Woyach, Jennifer A. |
author_facet | Hyak, Jonathan M. Huang, Ying Rogers, Kerry A. Bhat, Seema A. Grever, Michael R. Byrd, John C. Kittai, Adam S. Jones, Dan Miller, Cecelia R. Woyach, Jennifer A. |
author_sort | Hyak, Jonathan M. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9631640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-96316402022-11-04 Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes Hyak, Jonathan M. Huang, Ying Rogers, Kerry A. Bhat, Seema A. Grever, Michael R. Byrd, John C. Kittai, Adam S. Jones, Dan Miller, Cecelia R. Woyach, Jennifer A. Blood Adv Research Letter American Society of Hematology 2022-09-01 /pmc/articles/PMC9631640/ /pubmed/35834733 http://dx.doi.org/10.1182/bloodadvances.2022007708 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
spellingShingle | Research Letter Hyak, Jonathan M. Huang, Ying Rogers, Kerry A. Bhat, Seema A. Grever, Michael R. Byrd, John C. Kittai, Adam S. Jones, Dan Miller, Cecelia R. Woyach, Jennifer A. Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes |
title | Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes |
title_full | Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes |
title_fullStr | Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes |
title_full_unstemmed | Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes |
title_short | Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes |
title_sort | combined bcl2 and btk inhibition in cll demonstrates efficacy after monotherapy with both classes |
topic | Research Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631640/ https://www.ncbi.nlm.nih.gov/pubmed/35834733 http://dx.doi.org/10.1182/bloodadvances.2022007708 |
work_keys_str_mv | AT hyakjonathanm combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT huangying combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT rogerskerrya combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT bhatseemaa combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT grevermichaelr combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT byrdjohnc combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT kittaiadams combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT jonesdan combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT millerceceliar combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses AT woyachjennifera combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses |